Current Progress in Dengue Vaccine Clinical Trial

Dengue is one of the most important vector-borne viral diseases. Global phenomena such as urbanization and international travel are key factors in facilitating the spread of dengue causing major public health problems worldwide. There are four serotypes of dengue viruses (DENV), each serotype of DENV is capable of causing self-limited dengue fever (DF) or dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) by a relatively high mortality rate and/or high sequelae rate in survivors. No cure for dengue exists; treatment is limited to rehydration therapy, and with vector control strategies proving to be relatively ineffective. Moreover dengue life cycles are maintained between arthropod vectors and amplifying/reservoir hosts in the absence of humans, eradication of dengue might be extremely difficult. So vaccine development is considered a reasonable method to prevent dengue infections. In this article, we summarize the current dengue vaccine candidates in clinical trials, and discuss the directions and problems in vaccines development.

並列關鍵字

Dengue ； tetravalent ； vaccine introduction

國際替代計量

全文下載

主題瀏覽